Caribou Biosciences Crescita futura

Future criteri di controllo 2/6

Si prevede che gli utili di Caribou Biosciences diminuiranno a 6.1% all'anno, mentre si prevede che i suoi ricavi annuali cresceranno a 66.7% all'anno. Si prevede che l'EPS diminuirà di 0.2% all'anno. Si prevede che il ritorno sul capitale proprio sarà -36.7% in 3 anni.

Informazioni chiave

-6.1%

Tasso di crescita degli utili

-0.2%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	28.3%
Tasso di crescita dei ricavi	66.7%
Rendimento futuro del capitale proprio	-36.7%
Copertura analitica	Good
Ultimo aggiornamento	15 Nov 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Shares Bounce 25% But Its Business Still Trails The Industry

Nov 05

Caribou Biosciences: CB-010, chRDNA Technology Continue To Show Promise In Gene Editing

Sep 30

Here's Why We're Watching Caribou Biosciences' (NASDAQ:CRBU) Cash Burn Situation

Sep 06

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Share Price Boosted 39% But Its Business Prospects Need A Lift Too

Jul 26

Caribou Biosciences: Promising Gene Editing Therapies With Strong Buy Potential

Jul 03

Little Excitement Around Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Revenues As Shares Take 43% Pounding

Jun 05

Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value

Apr 18

More Unpleasant Surprises Could Be In Store For Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Shares After Tumbling 25%

Apr 17

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 25% Share Price Surge Not Quite Adding Up

Feb 15

Caribou Biosciences: Under The Radar With Catalysts Approaching

Feb 01

Caribou Biosciences (NASDAQ:CRBU) Is In A Good Position To Deliver On Growth Plans

Jan 10

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 28% Price Boost Is Out Of Tune With Revenues

Nov 18

Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth

Feb 24

Caribou Biosciences: Strong Momentum Possible If Higher Dose Shows Durability

Oct 12

Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth

Sep 16

Caribou Biosciences: Potential To Change CAR-T Landscape

Aug 01

Crispred CAR-T Cells In The Clinic

May 19

Caribou Biosciences, Inc. (NASDAQ:CRBU) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 13

Previsioni di crescita degli utili e dei ricavi

NasdaqGS:CRBU - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	58	-220	-185	-167	6
12/31/2025	9	-195	-169	-155	9
12/31/2024	9	-150	-148	-133	8
9/30/2024	11	-148	-132	-124	N/A
6/30/2024	33	-123	-133	-120	N/A
3/31/2024	33	-115	-115	-103	N/A
12/31/2023	34	-102	-105	-93	N/A
9/30/2023	35	-95	-108	-97	N/A
6/30/2023	14	-111	-99	-91	N/A
3/31/2023	15	-108	-106	-97	N/A
12/31/2022	14	-99	-98	-91	N/A
9/30/2022	13	-91	-93	-87	N/A
6/30/2022	13	-85	-86	-80	N/A
3/31/2022	11	-73	-78	-75	N/A
12/31/2021	10	-67	-36	-33	N/A
9/30/2021	8	-63	-22	-19	N/A
6/30/2021	5	-50	-14	-13	N/A
3/31/2021	12	-38	-4	-4	N/A
12/31/2020	12	-34	-35	-33	N/A
12/31/2019	6	-23	-33	-32	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che CRBU rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che CRBU rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che CRBU rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di CRBU ( 66.7% all'anno) crescerà più rapidamente del mercato US ( 8.9% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di CRBU ( 66.7% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che CRBU non sarà più redditizia tra 3 anni.

Caribou Biosciences Crescita futura

Future criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target increased by 11% to US$17.29

Consensus revenue estimates decrease by 18%, EPS upgraded

Price target decreased by 16% to US$16.63

Price target decreased by 8.0% to US$20.25

Consensus revenue estimates increase by 71%

Price target decreased by 7.8% to US$22.00

Recent updates

The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Caribou Biosciences, Inc

Price target increased by 11% to US$17.29

Consensus revenue estimates decrease by 18%, EPS upgraded

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Shares Bounce 25% But Its Business Still Trails The Industry

Insufficient new directors

Caribou Biosciences: CB-010, chRDNA Technology Continue To Show Promise In Gene Editing

Here's Why We're Watching Caribou Biosciences' (NASDAQ:CRBU) Cash Burn Situation

Caribou Biosciences Announces the Fda Has Granted Fast Track Designations to Cb-010 in Refractory Sle and to Cb-012 in Relapsed or Refractory Aml

Caribou Biosciences Appoints Tina Albertson as Chief Medical Officer

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

New major risk - Share price stability

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Share Price Boosted 39% But Its Business Prospects Need A Lift Too

Caribou Biosciences, Inc. Appoints Terri Laufer to Its Scientific Advisory Board

Caribou Biosciences: Promising Gene Editing Therapies With Strong Buy Potential

Price target decreased by 16% to US$16.63

Little Excitement Around Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Revenues As Shares Take 43% Pounding

Caribou Biosciences, Inc. Presents Encouraging Clinical Data from CB-010 Antler Phase 1 Trial in Second-Line Lbcl Patients At the 2024 American Society of Clinical Oncology (Asco) Annual Meeting

First quarter 2024 earnings: EPS misses analyst expectations

Caribou Biosciences, Inc., Annual General Meeting, Jun 13, 2024

Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value

More Unpleasant Surprises Could Be In Store For Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Shares After Tumbling 25%

Caribou Biosciences, Inc. Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus

Price target decreased by 8.0% to US$20.25

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 25% Share Price Surge Not Quite Adding Up

Chief Scientific Officer exercised options to buy US$212k worth of stock.

Caribou Biosciences: Under The Radar With Catalysts Approaching

Caribou Biosciences (NASDAQ:CRBU) Is In A Good Position To Deliver On Growth Plans

Caribou Biosciences, Inc. Appoints Tim Kelly as Chief Technology Officer

Syed Rizvi to Leave the Caribou Biosciences, Inc. as Chief Medical Officer, Effective from December 31, 2023

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 28% Price Boost Is Out Of Tune With Revenues

Consensus revenue estimates increase by 71%

Price target decreased by 7.8% to US$22.00

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Caribou Biosciences, Inc. Appoints Sundar Jagannath to its Scientific Advisory Board

Caribou Biosciences, Inc. Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Caribou Biosciences, Inc. Appoints Reigin Zawadzki as Chief People Officer

Consensus revenue estimates decrease by 19%, EPS upgraded

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 7.4% to US$24.86

Price target decreased by 8.6% to US$25.14

Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL

New minor risk - Shareholder dilution

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Caribou Biosciences Announces Appointment of Stephen J. Schuster, MD, to its Scientific Advisory Board

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth

Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Caribou Biosciences, Inc

Pomerantz Law Firm Announces the Filing of A Class Action Against Caribou Biosciences, Inc

Caribou Biosciences, Inc. Appoints Jason V. O'Byrne as Principal Accounting Officer

Caribou Biosciences Selects ROR1 as the Target for CB-020, an iPSC-derived Allogeneic CAR-NK Cell Therapy

Chief Scientific Officer exercised options to buy US$206k worth of stock.

Caribou Biosciences, Inc. Announces the FDA Granted Regenerative Medicine Advanced Therapy and Fast Track Designations to Cb-010, an Allogeneic Anti-Cd19 Car-T Cell Therapy

Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-Bcma Car-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Caribou Biosciences Presents Case Report on Long-Term Follow Up of First Patient Dosed in Phase 1 Antler Trial At the Lymphoma, Leukemia, & Myeloma Congress 2022

Caribou Biosciences: Strong Momentum Possible If Higher Dose Shows Durability

Vice President of Finance & Controller recently sold US$108k worth of stock

Insider exercised options to buy US$314k worth of stock.

Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth

Chief Scientific Officer exercised options and sold US$369k worth of stock

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Caribou Biosciences: Potential To Change CAR-T Landscape

Caribou Biosciences, Inc. Announces Board Changes

Caribou Biosciences, Inc., Annual General Meeting, Sep 20, 2022

Caribou Biosciences, Inc.(NasdaqGS:CRBU) dropped from Russell 2000 Growth Index

Caribou Biosciences, Inc. Reports Positive Additional Data from CB-010 Allogeneic CAR-T Cell Therapy Phase 1 ANTLER Trial at the European Hematology Association (EHA) 2022 Hybrid Congress